sorafenib has been researched along with bilirubin in 25 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (bilirubin) | Trials (bilirubin) | Recent Studies (post-2010) (bilirubin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 25,921 | 1,337 | 5,871 |
| Protein | Taxonomy | sorafenib (IC50) | bilirubin (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 3.3884 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.3183 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 8 (32.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fischer, L; Herden, U; Nashan, B; Schäfer, H; Sterneck, M; von Baehr, V | 1 |
| Abbas, H; Bancelin, N; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dauphin, A; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Ropert, S; Taieb, F; Thomas-Schoemann, A; Tod, M; Vidal, M | 1 |
| Bruix, J; Dominguez, S; Germanidis, G; Greten, TF; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Nadel, A; Raoul, JL; Ricci, S; Scherubl, H; Scheulen, ME; Sherman, M; Voliotis, D | 1 |
| Dahut, W; English, BC; Federspiel, J; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kim, A; Kirkland, CT; Kohn, E; Kummar, S; Peer, CJ; Richardson, ED; Sissung, TM; Troutman, SM; Venzon, D; Widemann, B; Woo, S; Yarchoan, R | 1 |
| Andersen, KJ; Hamilton-Dutoit, S; Kannerup, AS; Knudsen, AR; Ladekarl, M; Mortensen, FV; Nyengaard, JR; Sasanuma, H | 1 |
| Agrogiannis, G; Chatziioannou, AN; Fokas, D; Kavatzas, N; Kostomitsopoulos, NG; Loxas, D; Malagari, K; Siskos, AP; Tamvakopoulos, C; Tsigkou, O | 1 |
| Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O | 1 |
| Blanc, JF; Campillo-Gimenez, B; Collins, P; Darby, S; Edeline, J; Evans, J; Hubner, RA; Iwuji, C; Johnson, P; King, J; Ma, YT; Meyer, T; Muazzam, I; Palmer, DH; Patel, K; Ross, P; Sumpter, K; Swinson, D | 1 |
| Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT | 1 |
| Arizumi, T; Bettinger, D; Burlone, ME; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sharma, R; Thimme, R; Ward, C; Yen, C | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kee, KM; Kuo, YH; Lu, SN; Rau, KM; Wang, JH; Wu, IP | 1 |
| Chao, Y; Chen, YT; Hou, MC; Huang, YH; Huo, TI; Lee, FY; Lee, MH; Lee, PC; Li, CP; Lin, HC; Su, CW | 1 |
| Blanc, JF; Campillo-Gimenez, B; Edeline, J; Faluyi, O; Ghazi, S; King, J; Ma, YT; Mathurin, J; Meyer, T; Palmer, DH | 1 |
| Deguchi, A; Hiasa, Y; Hiraoka, A; Hirooka, M; Imai, M; Ishikawa, T; Joko, K; Koizumi, Y; Kudo, M; Kumada, T; Michitaka, K; Ochi, H; Shimada, N; Tada, T; Tajiri, K; Toyoda, H; Tsuji, K | 1 |
| Kang, MK; Lee, HJ; Park, JG | 1 |
| Deguchi, A; Hiasa, Y; Hiraoka, A; Hirooka, M; Imai, M; Ishikawa, T; Joko, K; Koizumi, Y; Kumada, T; Michitaka, K; Ochi, H; Shimada, N; Tada, T; Tajiri, K; Tanaka, J; Toyoda, H; Tsuji, K | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, IH; Lin, ZY; Tsai, YS; Yeh, ML; Yu, ML | 1 |
| Berhane, S; Bettinger, D; Blanc, JF; Bonnett, LJ; Cucchetti, A; De Man, RA; Edeline, J; Eskens, FALM; Johnson, PJ; Klümpen, HJ; Labeur, TA; Meyer, T; Takkenberg, RB; Ten Cate, DWG; Van Delden, OM; Van Vugt, JLA | 1 |
| Fujishiro, M; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Ito, T; Kuzuya, T; Muto, H | 1 |
| Bargellini, I; Benito, A; Gebauer, B; Iezzi, R; Ingrisch, M; Loewe, C; Malfertheiner, P; Öcal, O; Pech, M; Peynircioglu, B; Ricke, J; Seidensticker, M; Sengel, C; Ümütlü, MR; van Delden, O; Vandecaveye, V; Zech, CJ | 1 |
| Fidan, E; Fidan, S; Kazaz, N; Merev, E | 1 |
| Kuwano, A; Masumoto, A; Morita, Y; Motomura, K; Nagasawa, S; Tanaka, K; Yada, M | 1 |
| Chen, J; Ding, X; Li, L; Li, W; Li, X; Zhang, Y | 1 |
| Ang, C; Balcar, L; Bettinger, D; Cammarota, A; Cheon, J; Chon, HJ; Cortellini, A; D'Alessio, A; Fulgenzi, CAM; Gaillard, VE; Galle, PR; Huang, YH; Kudo, M; Marron, TU; Masi, G; Napolitano, A; Naqash, AR; Nishida, N; Personeni, N; Phen, S; Pinato, DJ; Pinter, M; Pressiani, T; Rimassa, L; Saeed, A; Salani, F; Scheiner, B; Schönlein, M; Schulze, K; Sharma, R; Singal, AG; Vivaldi, C; Vogel, A; von Felden, J; Wege, H; Wietharn, B; Wu, L | 1 |
| Aratake, Y; Harada, S; Higuchi, N; Hioki, T; Kohjima, M; Koyanagi, T; Kuniyoshi, M; Kuwano, A; Morita, Y; Motomura, K; Mutsuki, T; Nagasawa, S; Nakamura, T; Nakamuta, M; Nakashima, M; Ooe, M; Ooho, A; Satoh, T; Senju, T; Sugimoto, R; Tada, S; Tanaka, K; Tanaka, M; Tanaka, Y; Uchimura, K; Ueda, A; Yada, M; Yamashita, N; Yoshimoto, T | 1 |
1 review(s) available for sorafenib and bilirubin
| Article | Year |
|---|---|
Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal.
Topics: Bilirubin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; Sorafenib | 2022 |
4 trial(s) available for sorafenib and bilirubin
| Article | Year |
|---|---|
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; alpha-Fetoproteins; Antineoplastic Agents; Aspartate Aminotransferases; Benzenesulfonates; Bilirubin; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2012 |
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease Progression; Exanthema; Fatigue; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Serum Albumin; Serum Albumin, Human; Sorafenib; Treatment Outcome | 2015 |
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Topics: Adult; Aged; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Serum Albumin; Sorafenib | 2017 |
Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Prognosis; Sorafenib; Tumor Burden | 2022 |
20 other study(ies) available for sorafenib and bilirubin
| Article | Year |
|---|---|
Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Female; Humans; Male; Neoplasms; Niacinamide; Orosomucoid; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; Serum Albumin; Sorafenib; Young Adult | 2011 |
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Bilirubin; Clinical Trials as Topic; Disease-Free Survival; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasms; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Pilot Projects; Polymorphism, Genetic; Prostatic Neoplasms; Pyridines; Sorafenib; UDP-Glucuronosyltransferase 1A9 | 2012 |
Sorafenib inhibits liver regeneration in rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Bilirubin; Body Weight; Cell Proliferation; Hepatectomy; Ki-67 Antigen; Liver; Liver Regeneration; Niacinamide; Organ Size; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Wistar; Sorafenib; Time Factors | 2013 |
Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study.
Topics: Alanine Transaminase; Angiogenesis Inhibitors; Animals; Bilirubin; Chemoembolization, Therapeutic; Chromatography, High Pressure Liquid; Ethiodized Oil; Feasibility Studies; gamma-Glutamyltransferase; Hepatic Artery; Liver; Male; Models, Animal; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Tandem Mass Spectrometry | 2013 |
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Female; France; Humans; Liver Neoplasms; Lung; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Serum Albumin; Severity of Illness Index; Sorafenib; Survival Analysis; United Kingdom; Young Adult | 2016 |
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides | 2017 |
The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Databases, Factual; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Prospective Studies; Sorafenib | 2017 |
Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
Topics: Aged; Albuminuria; Antineoplastic Agents; Bilirubin; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Rate; Treatment Failure | 2017 |
Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Decision-Making; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Reproducibility of Results; Retreatment; Retrospective Studies; Risk Factors; Serum Albumin, Human; Sorafenib; Treatment Failure | 2018 |
Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Decision Support Techniques; Disease-Free Survival; Female; France; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Serum Albumin, Human; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden; United Kingdom | 2017 |
Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.
Topics: Adult; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; International Normalized Ratio; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome | 2018 |
Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; ROC Curve; Serum Albumin, Human; Sorafenib; Survival Rate; Time Factors | 2019 |
The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment.
Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Prognosis; Sorafenib | 2019 |
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Reproducibility of Results; Retrospective Studies; Risk Factors; Serum Albumin, Human; Sorafenib; Survival Analysis | 2020 |
Transient deterioration of albumin-bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation: A STROBE-compliant retrospective observational study.
Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Pharmacological; C-Reactive Protein; Carcinoma, Hepatocellular; Correlation of Data; Drug Monitoring; Drug Screening Assays, Antitumor; Female; Humans; Japan; Liver; Liver Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Staging; Phenylurea Compounds; Quinolines; Serum Albumin; Sorafenib | 2021 |
The Relationship between albumin-Bilirubin grade and survival in hepatocelluler carcinoma patients treated with sorefanib.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Bilirubin; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Sorafenib; Young Adult | 2022 |
Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Prognosis; Retrospective Studies; Sorafenib | 2022 |
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Topics: Albumins; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bilirubin; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Sorafenib; Venous Thrombosis | 2022 |
Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.
Topics: alpha-Fetoproteins; Bilirubin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; Ramucirumab; Retrospective Studies; Sorafenib | 2022 |